Abstract

Overexpression of Sperm Acrosomal SLLP1 Binding protein (SAS1B) in various cancer types, including uterine cancer cells, was discovered a few years ago, and different monoclonal antibodies (anti-SAS1B) that specifically bind to SAS1B antigens were developed. Labeling of these antibodies with radionuclides can provide an opportunity for imaging and radioimmunotherapy. The objective of this study was to label anti-SAS1B (SB5) with Zirconium-89 (89Zr) for PET imaging and determine its biodistribution. Anti-SAS1B (SB5) antibody was labeled with 89Zr indirectly using the chelator desferrioxamine B (DFO), which is currently a best linker for 89Zr. The antibody, SB5, was first conjugated to DFO with a ratio of 1:5 and then labeled with 250 μCi of 89Zr. Results of PET imaging in mouse-bearing uterine cancer tumor showed a limited uptake. The bio-distribution study matched the PET imaging and confirmed the uptake by the tumor, and the accumulation in bones. In conclusion, labeling of anti-SAS1B could provide an effective way of uterine cancer detection and treatment progression.

Highlights

  • Molecular imaging has had a transformative impact on academic research, industry, and the clinical field [1]

  • Overexpression of Sperm Acrosomal SLLP1 Binding protein (SAS1B) in various cancer types, including uterine cancer cells, was discovered a few years ago, and different monoclonal antibodies that bind to SAS1B antigens were developed

  • Labeling of anti-SAS1B could provide an effective way of uterine cancer detection and treatment progression

Read more

Summary

Introduction

Molecular imaging has had a transformative impact on academic research, industry, and the clinical field [1]. Overexpression of SAS1B protein on the cell surface in many types of tumors, including uterine tumor, was discovered by Dr John C, Herr and coworkers, who developed different monoclonal antibodies (anti-SAS1B) against this protein and demonstrated specific binding to SAS1B [11]. Because of their sensitivity and specificity and biological half-live Monoclonal antibodies have been used for more than two decades to target cancer cells [12] [13]. Diagnosis and treatment assessment is crucial for cancer therapy [17]

Objectives
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.